™E Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders By Investing.com

BERLIN–( BUSINESS WIRE )– Regulatory News:

E Pharma NV™ (Euronext Growth Paris: AL™E) (Paris: AL™E), The biotechnology company, which is focused on developing novel therapies to treat cancer by targeting the tumor microenvironment (™), today announced that the company's Annual General Meeting (AGM) will be held at 01.30pm CEST on 27 June 2024. at the Freshfields offices. Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, Netherlands.

The annual accounts for the year ending 31 December 2023, the report of the Board of Directors for 2023, the invitation to the Ordinary General Assembly, the agenda, explanatory notes to the agenda, instructions and documents for participation and voting in person or by proxy in the next Annual General Assembly are available on the Company’s website, in a dedicated section on the Corporate Governance page. These documents are also available at the company's offices located at Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany to shareholders and persons entitled to attend the meeting who will, upon request, receive a copy free of charge.

One of the items on the agenda of the General Assembly will be a vote on the nomination of a new Board member. Taking into account the development, performance and current strategy of the company, the Supervisory Board has made a binding nomination for Dr. Lee Chalob to be the fourth member of the Supervisory Board.

Dr. Lee Shaloub (New York, USA; 60 years) has a unique combination of experience in brain cancer biotechnology development and deep knowledge of the financial industry. He was a co-founder of Oncoceutics, a clinical-stage drug discovery and development company with a novel brain cancer drug, and as CEO, led a transformative acquisition of the company by Chimerix (NASDAQ:) in January 2021 for $78 million plus over that. Up to $360 million in conditional payments and royalties ranging from 15-20% on sales. Additionally, Dr. Shalob served as Chief Operating Officer of Oncoceutics from 2016 to 2020 and Chief Business Officer from Oncoceutics' founding in 2009 to 2016. Prior to co-founding Oncoceutics, Dr. Shalob attended Albert Einstein College of Medicine, graduating with a Ph.D. in Medicine in 2008. Prior to entering medical school, Dr. Schallop spent more than 19 years in the financial sector at a number of major Wall Street firms, including Morgan Stanley, JPMorgan, Credit Suisse, and Bank of America Securities. . From 1985 to 1993, he was an investment banker, and his fundraising activities included more than 10 initial public offerings, the largest of which raised more than $700 million. From 1993 to 2004, he worked as a research analyst and authored more than 1,000 reports covering more than 50 different publicly traded companies, earning a reputation for groundbreaking research. Dr. Chalob serves as an observer to the Board of Directors at Chemrix Company . He is a member of the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania. He is a summa cum laude graduate of the University of Pennsylvania, where he earned dual degrees from the university's Wharton School and College of Arts and Sciences.

Under Dutch law and the company's articles of association, the persons entitled to attend and vote at the annual general meeting are shareholders of the company (which for the purposes of this notice includes beneficial owners under Dutch law) and who (i) are registered as a shareholder in one of the administrative registers of the participating brokers ( indirectly) at Euroclear France on 30 May 2024 (the Registration Date) after processing all debit and credit entries in accordance with the Registration Date and (ii) notifying the Company by 05.00pm CEST on 20 June 2024 of their attendance in writing or electronically (contact details available On the company's website).

About E-Pharma™

E-Pharma™ It is a clinical stage company focused on developing new therapies to treat the most aggressive types of cancer. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (™E) and the cancer immune cycle by breaking down tumor protection barriers against the immune system and preventing tumor repair. By neutralizing the chemicals in E™, ™E Pharma This approach works in combination with other forms of treatment to weaken the tumor's defenses and allow for a greater therapeutic effect. In the Phase 1/2 clinical trial of GLORIA, E-Pharma™ The company is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who would not clinically benefit from standard chemotherapy. E-Pharma™ High-level data were presented from the three dose-escalation combinations of NOX-A12 combined with radiotherapy for the GLORIA clinical trial, observing consistent tumor reduction and objective tumor responses. Additionally, the GLORIA expansion arm is evaluating the safety and efficacy of NOX-A12 in other populations where interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab indicate deeper and more durable responses and improved survival. The US Food and Drug Administration (FDA) has approved the design of a randomized phase II trial in the treatment of glioblastoma and glioblastoma. E-Pharma™ NOX-A12 in combination with radiation therapy and bevacizumab has been granted Fast Track designation by the FDA for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug (ODD) designation for glioblastoma in the United States and glioma in Europe. E-Pharma™ presented generally encouraging final data on survival and safety from its NOX-A12 combination trial with Keytruda ® in patients with metastatic colorectal and pancreatic cancer, which was published in the Journal of Cancer Immunotherapy in October 2021. In its second collaboration with MSD/Merck in a phase 2 study , OPTIMUS, to further evaluate the safety and efficacy of NOX-A12 in combination with Merck's Keytruda ® and two different chemotherapy regimens as second-line treatment in patients with metastatic pancreatic cancer. The trial design has been approved in France, Spain, and the United States. The company's second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. ™E Pharma Several solid tumors are being studied for further clinical development. More information can be found at: www.tmepharma.com.

E-Pharma™ ® and E-Pharma™ Logo are registered trademarks.

Keytruda ® is a registered trademark of Merck Sharp (OTC:) and Dohme Corp.

Visit ™E Pharma on LinkedIn And Twitter.

About Gloria's study

Gloria (NCT04121455) is ™E Pharma Dose escalation, phase 1/2 study of NOX-A12 in combination with radiation therapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT (refractory to standard chemotherapy). GLORIA is also evaluating the safety and effectiveness of NOX-A12 three additional arms that combine NOX-A12 with: a. Radiotherapy in patients with complete tumor resection; B. Radiotherapy and bevacizumab. and C. radiotherapy and pembrolizumab.

About studying Optimus

Optimus (NCT04901741) is ™E Pharma A planned open-arm phase II study of NOX-A12 in combination with pembrolizumab and irinotecan nanoliposomal/5-FU/leucovorin or gemcitabine/nab-paclitaxel in patients with satellite-stable stable metastatic pancreatic cancer.

Disclaimer

The translation of any press release into languages ​​other than English is intended solely to provide convenience to the non-English reading public. The company has tried to provide an accurate translation of the original English text, but due to the nuances of translation into another language, slight discrepancies may exist. This press release includes certain disclosures that contain “forward-looking statements.” Forward-looking statements are based on… E-Pharma™ Projections are current and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks inherent in oncology drug development, including clinical trials and their timing. ™E Pharma Ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. The forward-looking statements contained in this announcement are made as of the date hereof E-Pharma™ We assume no responsibility to update this information except as required by applicable law.

View source version on Businesswire.com: https://www.businesswire.com/news/home/20240526935010/en/

For more information please contact:
E-Pharma NV™
Aram Mangasaryan, Ph.D., CEO
phone. +49 (0) 30 16637082 0
investors@tmepharma.com

Investor relations and media:
LifeSci Consultants
Guillaume van Rentergem
phone. +41 (0) 76 735 01 31
gvanrenterghem@lifesciadvisors.com

newcap
Arthur Rowell
phone. +33 (0) 1 44 71 00 15
arouille@newcap.fr

Source: E Pharma NV™